Please sign in to follow a disease.
Can daily texts and peer support keep psychiatric patients out of hospital?
NCT ID NCT05133726
First seen Sep 11, 2026 · Last updated Sep 11, 2026
Summary
People leaving acute psychiatric care in Alberta often wait months for a follow-up appointment, which raises the risk of relapse and a return to hospital. This trial tests a low-cost program that sends daily supportive text messages based on cognitive behavioral therapy and pairs patients with peer supporters who have lived through similar mental health challenges. Researchers will track whether participants are readmitted to acute psychiatric care within 30 days of discharge and measure changes in psychological distress. The study enrolls adults aged 18 to 65 who have a mental health diagnosis, are preparing for discharge, and have a phone that can receive texts.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Daily supportive text messages and peer support from people in recovery
- What this could lead to
- If it works, this could give hospitals a low-cost way to help people stay well after leaving psychiatric care and avoid returning to the emergency department.
- What could go wrong
- Texts and peer support may not be enough to prevent readmission for people facing long waits for follow-up care. The approach relies on participants having a phone and being able to read messages, which may limit who benefits.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
1,149 people
The number who actually took part.
- Started
-
Mar 2022
- Finished
-
Jun 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients who are 18 or 65 years of age * Able to provide informed written consent have been diagnosed with mental health condition, and are ready for discharge. * Patients should have a mobile device capable of receiving text messages Exclusion Criteria: * Patients will be ineligible if they do not meet the above inclusion criteria, * If they have an addiction disorder but not a mental health diagnosis * Are not capable of reading text messages from a mobile device or if they know they will be out of town during the 12-month follow-up period. * Patients are also ineligible if they do not consent to take part in the study,
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Psychiatric illness are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Alberta Hospital
Edmonton, Alberta, T5J2J7, Canada
-
Foothills Hospital
Calgary, Canada
-
Grey Nuns Hospital
Edmonton, Alberta, T6L5X8, Canada
-
Misericordia Community Hospital
Edmonton, Alberta, T5R4H5, Canada
-
Northern Lights Regional Health Centre
Fort McMurray, Alberta, Canada
-
Royal Alexander Hospital
Edmonton, Alberta, T5H2V1, Canada
-
University of Alberta Hospital
Edmonton, Alberta, T6G2R3, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.